Shire (LON: SHP)‘s stock had its “buy” rating restated by analysts at Jefferies Group in a research report issued to clients and investors on Monday. They currently have a $38.62 (2400 GBX) price target on the stock.

A number of other analysts have also recently weighed in on SHP. Analysts at Societe Generale reiterated a “buy” rating on shares of Shire in a research note to investors on Wednesday, October 24th. They now have a $36.32 price target on the stock. Separately, analysts at Exane BNP Paribas reiterated an “outperform” rating on shares of Shire in a research note to investors on Friday, October 19th. Finally, analysts at Bryan Garnier & Cie reiterated a “buy” rating on shares of Shire in a research note to investors on Friday, September 21st. They now have a $36.13 price target on the stock.

Shares of Shire opened at 1743.7189 on Monday. Shire has a one year low of GBX 1706.00 and a one year high of GBX 2316.00. The company’s market cap is £9.808 billion.

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.